410 related articles for article (PubMed ID: 20041858)
1. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models.
Hu LF; Lu M; Tiong CX; Dawe GS; Hu G; Bian JS
Aging Cell; 2010 Apr; 9(2):135-46. PubMed ID: 20041858
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats.
Yin WL; Yin WG; Huang BS; Wu LX
Neurosci Lett; 2017 Sep; 657():45-52. PubMed ID: 28764908
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Thakur P; Nehru B
Neuroscience; 2013 Feb; 231():420-31. PubMed ID: 23159314
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Crotty S; Fitzgerald P; Tuohy E; Harris DM; Fisher A; Mandel A; Bolton AE; Sullivan AM; Nolan Y
Eur J Neurosci; 2008 Jan; 27(2):294-300. PubMed ID: 18190522
[TBL] [Abstract][Full Text] [Related]
5. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
6. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
Li LY; Zhao XL; Fei XF; Gu ZL; Qin ZH; Liang ZQ
Acta Pharmacol Sin; 2008 May; 29(5):539-47. PubMed ID: 18430361
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism.
Lopez-Real A; Rey P; Soto-Otero R; Mendez-Alvarez E; Labandeira-Garcia JL
J Neurosci Res; 2005 Sep; 81(6):865-73. PubMed ID: 16015598
[TBL] [Abstract][Full Text] [Related]
8. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
9. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease.
Shim JS; Kim HG; Ju MS; Choi JG; Jeong SY; Oh MS
J Ethnopharmacol; 2009 Nov; 126(2):361-5. PubMed ID: 19703534
[TBL] [Abstract][Full Text] [Related]
10. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Tapias V; Cannon JR; Greenamyre JT
J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
[TBL] [Abstract][Full Text] [Related]
11. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
12. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Schmidt WJ; Alam M
J Neural Transm Suppl; 2006; (70):273-6. PubMed ID: 17017541
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of glyceryl nonivamide against microglia-like cells and 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells.
Lin YC; Uang HW; Lin RJ; Chen IJ; Lo YC
J Pharmacol Exp Ther; 2007 Dec; 323(3):877-87. PubMed ID: 17855475
[TBL] [Abstract][Full Text] [Related]
14. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
16. Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease.
Falk T; Zhang S; Sherman SJ
Neurosci Lett; 2009 Jul; 458(2):49-52. PubMed ID: 19442875
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.
Kim YJ; Park HJ; Lee G; Bang OY; Ahn YH; Joe E; Kim HO; Lee PH
Glia; 2009 Jan; 57(1):13-23. PubMed ID: 18661552
[TBL] [Abstract][Full Text] [Related]
18. Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease?
Wang S; Hu LF; Yang Y; Ding JH; Hu G
Neuropharmacology; 2005 Jun; 48(7):984-92. PubMed ID: 15857625
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action.
Park HJ; Lee PH; Ahn YW; Choi YJ; Lee G; Lee DY; Chung ES; Jin BK
Eur J Neurosci; 2007 Jul; 26(1):79-89. PubMed ID: 17581257
[TBL] [Abstract][Full Text] [Related]
20. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
